Nano-X Imaging

Nano-X uses a cold-cathode X-ray source with silicon-based field emitters, rather than conventional heated tungsten filaments. The firm claims this architecture enables lower manufacturing cost, reduced heat generation, and a multi-source 3D tomosynthesis scanner called Nanox.ARC. The underlying source technology was acquired from a Japanese research institution and further developed in Israel (per the firm, 2019).

Revenue comes from three primary streams: direct sales and leases of its FDA-cleared digital X-ray systems, per-click fees from cloud-based AI image analysis software, and fees from teleradiology interpretation services provided by its USARAD subsidiary. The firm has publicly stated a long-term ambition to offer its multi-source scanner under a pay-per-scan pricing model, but this depends on widespread regulatory clearance and commercial contracts that are still in early stages.

It operates as both. The hardware division designs and sells imaging equipment, while its wholly owned teleradiology subsidiary interprets scans for hospitals and clinics. This vertical integration — manufacturing, software, and professional interpretation under one corporate structure — is atypical in the imaging industry, where these functions are usually unbundled.

The single-source Nanox.CLOUD digital X-ray system received FDA 510(k) clearance in April 2021. The multi-source Nanox.ARC received FDA 510(k) clearance in May 2023. The firm also holds CE marking in Europe and has secured regulatory approvals in Israel and certain African and Asian markets (per firm announcements, 2021–2023).

Acquired through the 2018 purchases of USARAD Holdings and Medical Diagnostics Web, the teleradiology unit provides a built-in interpretation network for scans captured on Nano-X hardware. This creates a closed loop where the firm supplies the imaging device, the AI triage software, and the final radiologist read. The division operates in all 50 US states and over 20 countries.

As a publicly traded company, Nano-X reports quarterly financials. Through its filings, the firm has reported operating losses since inception, consistent with a pre-commercialization stage for its core multi-source scanner and heavy R&D investment. Revenue from existing products and teleradiology services has grown but has not reached profitability thresholds (per SEC filings, 2020–2024).

In medical imaging hardware, incumbents include Siemens Healthineers, GE HealthCare, and Philips. In teleradiology, competitors include vRad (MEDNAX Radiology Solutions) and Radiology Partners. Nano-X's market position is unique in attempting to combine all three layers — OEM, AI software, and radiology reads — under a single entity, which creates competitive overlap with a broad set of players.